SEARCH

SEARCH BY CITATION

References

  • 1
    Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.
  • 2
    United Network for Organ Sharing, Policy 3.6: Available at: http://www.unos.org/policiesandbylaws/policies.asp?resources=true. Accessed July 18, 2006.
  • 3
    Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004;127: S261S267.
  • 4
    Sharma P, Balan V, Hernandez JL et al. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl 2004; 10: 3641.
  • 5
    Sharma P, Harper AM, Hernandez JL et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transpl 2006; 6: 19571962.
  • 6
    Roberts JP. Role of adult living liver donation in patients with hepatocellular cancer. Liver Transpl 2003; 9(Suppl 2): S60S63.
  • 7
    Kulik L, Abeccassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127: S277S282.
  • 8
    Kulik LM, Freise CE, Lok AS, Stravitz RT, Hulbert-Shearon TE, Fisher RA, for the A2ALL Study Group. A comparison of adult living donor (LDLT) to deceased donor liver transplant (DDLT) for hepatocellular carcinoma (HCC): Data from the A2ALL study [Abstracct]. Hepatology 2005; 42: 199A.
  • 9
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646649.
  • 10
    Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002; 346: 10741082.
  • 11
    Edmondson H, Steiner P. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954; 1: 462503.
  • 12
    Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 13941403.
  • 13
    Yao FY, Bass NM, Nikolai B et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl 2003; 9: 684692.
  • 14
    Maddala YK, Stadheim L, Andrews JC et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: Outcome with chemoembolization. Liver Transpl 2004; 10: 449455.
  • 15
    Yao FY, Bass NM, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl 2004; 10: 621630.
  • 16
    Todo S, Furukawa H, and the Japanese Study group on organ transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg 2004; 240: 451461.
  • 17
    Hwang S, Lee SG, Joh JW et al. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: Comparison between cadaveric donor and living donor liver transplantation. Liver Transpl 2005; 11: 12651272.
  • 18
    Jonas S, Bechstein WO, Steinmuller T et al. Vascular invasion and histologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 10801086.
  • 19
    Hemming AW, Cattral MS, Reed AI, Van der Warf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233: 652659.
  • 20
    Pawlik TM, Delman KA, Vauthey JN et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11: 10861092.
  • 21
    Yao FY. Selection criteria for liver transplantation in patients with hepatocellular carcinoma: Beyond tumor size and number?[Editorial]. Liver Transpl 2006; 12: 11891191.
  • 22
    Katz DA, Voigt M, Dunn T, Wu YM, Rayhill S, Hunsicker L. Increasing waiting time predicts post-transplant hepatocellular recurrence [Abstract]. World Transplant Congress 2006; Boston , MA (Abstract # 838).
  • 23
    Yao FY, Kinkhabwala M, LaBerge J et al. The impact of pre-operative loco-regional treatments on survival following liver transplantation for hepatocellular carcinoma. Am J Transpl 2005; 5: 795804.
  • 24
    Decaens T, Roudot-Thoraval F, Bresson-Hadni S et al. Impact of pre-transplantation transarterial chemoembolization on survival and recurrence after liver transplantation for heaptocellular carcinoma. Liver Transpl 2005; 11: 767775.
  • 25
    Porrett PM, Peterman H, Rosen M et al. Lack of benefit of pre-transplant loco-regional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006; 12: 665673.
  • 26
    Bharat A, Brown DB, Crippin JS et al. Pre-liver transplantation loco-regional adjuvant therapy for hepatocellular carcinoma as a strategy to improve long-term survival. J Am Coll Surg 2006; 203: 411420.
  • 27
    Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma; An evidence-based analysis. Am J Transpl 2006; 6: 26442650.
  • 28
    Yao FY, Hirose R, LaBerge J et al. A prospective study on down-staging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005; 11: 15051514.
  • 29
    Otto G, Herber S, Heise M et al. Response to transarterial chemoembolization as a biologic selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 12601267.